Sessions and exhibits designed to increase the
understanding of pharmaceutical formulation needs.
By Annie Keller, Contributing Writer
FormulationX: Bringing the Pharma
Community Together for Discovery
Insight, Knowledge, and Success
There are four stages that are usually considered as being part of the product development cycle: Conception, design, realization, and service. Most in the pharma community are on page with the last cycle, but many are not as up to speed with the other three. With the increasing
demand for raw materials, chemicals, and intermediates to meet the needs of
the drug manufacturers, all four stages need to be fully understood.
FormulationX, a new feature debuting at INTERPHEX 2018, aims to help
fill that knowledge gap.
The new program brings together
pharma thought leaders and suppliers
for 14 no-cost technical sessions over
the three days of INTERPHEX. The
sessions aim to bring companies and
organizations focused on drug substance
and pharma/bio companies together
to network and exchange ideas.
In addition, exhibits by the companies will feature new technology
and innovation from all ends of the
product development cycle.
It is hoped that the sessions and
exhibits will enable groups to make
connections that will lead to increased
understanding of formulation needs.
It's estimated that the active pharmaceutical ingredient market will
grow 6. 3 percent by 2021. The excipient market is estimated to grow 7. 2
percent in that period of time.
"FormulationX was designed to meet
the needs of the North American market and drug substance industry pro-fessionals," explained Melissa Ashley,
senior vice president, INTERPHEX, in a
statement announcing the debut.
“Pharmaceutical and biotechnology
companies around the world expect an
increase in spend for raw materials, ex-
cipients, intermediates, fine chemicals,
and API in the coming years due to
the increasing demand for new drugs,
innovation in excipients, and new
technologies used in manufacturing,”
The main foundation sponsor, Elsevier, a global leader in science analytics,
currently publishes more than 2,500
journals and 35,000 e-books, all of
which aim to improve research, healthcare, and performance.
Another foundation sponsor is
Colorcon, a provider of technologies
and services for drug-dose design and
development. A Colorcon goal is to
encourage production of cost-effective pharmaceutical products within a
reduced development time frame.
Their research is devoted to developing new drug coating systems,
release technologies, and pharmaceutical excipients. The company also
provides training and webinars on
their research efforts.
A third sponsor, the Dow Chemical
Company, is the second largest chemical manufacturer in the world. Its main
products include performance plastics
A fourth sponsor is Azelis, a leader
in global distribution of specialty
Marcor is the final sponsor. A subdivision of Azelis, it provides ingredients for health, pharmaceutical, and
Dow’s Pharma Solutions division
includes cutting-edge polymers and
topical ingredients that maximize drug
delivery, whether oral, transdermal, or
topical. Another key focus is pharmaceutical excipients and active pharmaceutical ingredients.
“Increasing the presence of drug
substance suppliers catering to the
needs of targeted attendee groups will
further strengthen the value proposition
of INTERPHEX offering an even more
robust platform of formulation through
products, and services,” Ashley said.
“With the debut of FormulationX,
INTERPHEX is well-positioned to continue its leadership role in delivering
value to our customers and access to a
full-range of technologies and industry
expertise to address challenges faced
by the industries we serve,” she added.
FormulationX programs and exhibits are located at Booth 4005 in the